ROMO1 (Reactive Oxygen Modulator 1), also known as CCDC111 or HMO-Sh, is a mitochondrial membrane protein implicated in regulating reactive oxygen species (ROS) production and mitochondrial dynamics. First identified in 2005. it plays a critical role in maintaining mitochondrial membrane potential, apoptosis, and cellular stress responses. Dysregulation of ROMO1 is linked to various pathologies, including cancer progression, neurodegenerative diseases, and metabolic disorders. Its overexpression has been observed in multiple cancers, where it promotes tumor growth and chemoresistance by enhancing ROS-mediated signaling pathways.
ROMO1 antibodies are essential tools for studying its expression, localization, and function. These antibodies (polyclonal or monoclonal) are typically developed against specific epitopes of human ROMO1 and validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use them to investigate ROMO1's interaction partners, such as components of the mitochondrial permeability transition pore, and its role in oxidative stress pathways. Recent studies also explore ROMO1 as a potential therapeutic target, driving demand for reliable antibodies in both diagnostic and drug development contexts. However, challenges remain in ensuring antibody specificity due to ROMO1's structural similarities with other mitochondrial proteins.